van de Pol Natasja, van der Woude C Janneke, Vis Marijn, van Doorn Martijn B A, Schrauwen Saskia L, Cetinözman-Teunissen Fatos, West Rachel L, de Vries Annemarie C
Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Department of Rheumatology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Infection. 2025 Feb;53(1):317-327. doi: 10.1007/s15010-024-02373-z. Epub 2024 Aug 22.
Patients with Immune Mediated Inflammatory Diseases (IMIDs) using immunosuppressive therapy are at increased risk of infections, including vaccine-preventable infections. In this study, we aimed to evaluate whether patients with IMIDs on systemic immunosuppressive therapy are vaccinated according to current guidelines.
A survey was sent out, between August 2022 and March 2023, to all patients with IMIDs that visited the departments of dermatology, rheumatology and gastroenterology at an academic and regional hospital in Rotterdam, the Netherlands. Patient-reported vaccination status was compared to the Dutch guidelines on vaccinations in patients with chronic inflammatory diseases.
A total of 1,905/5,987 patients responded to the survey (response rate 32%). After exclusion of patients without systemic immunosuppressive medication, the study population comprised 1,390 patients, median age 56 years (IQR 42-66) and 41% male. Most patients (92%) had been vaccinated according to the Dutch National Immunization Program. Before starting immunosuppressive therapy, 2% of the patients who were still considered at risk according to the Dutch guideline were vaccinated for measles, and 4% for diphtheria/tetanus/polio (DT-IPV). Additionally, 62% of patients received an annual influenza vaccine, 16% received a five-yearly pneumococcal vaccine, and 91% were fully vaccinated against COVID-19.
Patients with IMIDs on immunosuppressive therapy are not vaccinated in accordance with the guidelines. Implementation strategies to improve the vaccination rates for patients with IMIDs should specifically focus on vaccinating against measles and diphtheria/tetanus/polio, and periodic vaccination against pneumococcal and influenza infections.
使用免疫抑制疗法的免疫介导炎症性疾病（IMID）患者感染风险增加，包括疫苗可预防的感染。在本研究中，我们旨在评估接受全身免疫抑制治疗的IMID患者是否按照当前指南进行了疫苗接种。
2022年8月至2023年3月期间，向荷兰鹿特丹一家学术和地区医院皮肤科、风湿病科和胃肠病科就诊的所有IMID患者发送了一份调查问卷。将患者报告的疫苗接种状况与荷兰慢性炎症性疾病患者疫苗接种指南进行比较。
共有1905/5987名患者回复了调查（回复率32%）。排除未使用全身免疫抑制药物的患者后，研究人群包括1390名患者，中位年龄56岁（四分位间距42 - 66岁），男性占41%。大多数患者（92%）已按照荷兰国家免疫规划进行了疫苗接种。在开始免疫抑制治疗之前，根据荷兰指南仍被视为有风险的患者中，2%接种了麻疹疫苗，4%接种了白喉/破伤风/脊髓灰质炎（DT - IPV）疫苗。此外，62%的患者接种了年度流感疫苗，16%接种了每五年一次的肺炎球菌疫苗，91%的患者完成了新冠疫苗全程接种。
接受免疫抑制治疗的IMID患者未按照指南进行疫苗接种。提高IMID患者疫苗接种率的实施策略应特别侧重于麻疹、白喉/破伤风/脊髓灰质炎疫苗接种，以及肺炎球菌和流感感染的定期疫苗接种。
